Efficacy and safety of the COX-2 specific inhibitor valdecoxib in the management of osteoarthritis of the hip: a randomized, double-blind, placebo-controlled comparison with naproxen
- 30 April 2002
- journal article
- clinical trial
- Published by Elsevier BV in Osteoarthritis and Cartilage
- Vol. 10 (4), 290-296
- https://doi.org/10.1053/joca.2001.0510
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid ArthritisJAMA, 2000
- A Randomized Trial of the Efficacy and Tolerability of the COX-2 Inhibitor Rofecoxib vs Ibuprofen in Patients With OsteoarthritisArchives of Internal Medicine, 2000
- 4-[5-Methyl-3-phenylisoxazol-4-yl]- benzenesulfonamide, Valdecoxib: A Potent and Selective Inhibitor of COX-2Journal of Medicinal Chemistry, 2000
- Treatment of Osteoarthritis With Celecoxib, a Cyclooxygenase-2 Inhibitor: A Randomized Controlled TrialMayo Clinic Proceedings, 1999
- Cyclooxygenase in biology and diseaseThe FASEB Journal, 1998
- Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain.Proceedings of the National Academy of Sciences, 1994
- Risk of upper gastrointestinal bleeding and perforation associated with Individual non-steroidal anti-inflammatory drugsThe Lancet, 1994
- Risk for Serious Gastrointestinal Complications Related to Use of Nonsteroidal Anti-inflammatory DrugsAnnals of Internal Medicine, 1991
- Development of criteria for the classification and reporting of osteoarthritis: Classification of osteoarthritis of the kneeArthritis & Rheumatism, 1986
- A Seven‐Day variability study of 499 patients with peripheral rheumatoid arthritisArthritis & Rheumatism, 1965